Abraham L. Bayer

This study identifies T cell-derived IFNγ as a driver of ECM stiffening in HFpEF via LOXL3 in cardiac fibroblasts, showing therapeutic potential for targeting this pathway.

This study shows that chemotherapy activates fibroblasts in TNBC, promoting pro-invasive ECM production, and that nintedanib can suppress this effect.

This paper shows that targeting CIP4-CaNAβ2 signalosomes improves cardiac function and reduces remodeling after myocardial infarction in mice.

This study identifies CXCR3-CXCL9/10 axis as a therapeutic target for ICI-mediated myocarditis using mouse models and human patient data.